The knockout of P110α and P110β is a promising strategy with high efficiency in the reduction of MDR in more than one cancer cell types and can prosperously be facilitated for administration in combination with anticancer drugs and PI3K inhibitors [59]. Here, PIK3CB is linked to cancer.